We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioArctic, AbbVie Parkinson's Collaboration
News

BioArctic, AbbVie Parkinson's Collaboration

BioArctic, AbbVie Parkinson's Collaboration
News

BioArctic, AbbVie Parkinson's Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioArctic, AbbVie Parkinson's Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioArctic announced that it entered into a strategically important collaboration with AbbVie to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications.

Parkinson’s disease is the second most-common neurological disease, affecting more than 10 million people worldwide. Mutations in alpha-synuclein are strongly linked to development of Parkinson’s disease. Soluble aggregates of the alpha-synuclein protein are toxic to neurons and lead to the deposits that are a hallmark of the disease.

“AbbVie has shown a strong commitment to Parkinson’s disease and I am proud that they have chosen to collaborate with BioArctic. I am looking forward to a successful partnership that hopefully will result in a new innovative disease modifying treatment becoming available to the large number of patients suffering from Parkinson’s disease,” said Gunilla Osswald, CEO at BioArctic.


Advertisement